Verastem Inc (VSTM)

1.99
0.33 20.00
NASDAQ : Health Care
Prev Close 1.66
Open 1.62
Day Low/High 1.61 / 1.94
52 Wk Low/High 1.05 / 8.07
Volume 919.38K
Avg Volume 245.30K
Exchange NASDAQ
Shares Outstanding 36.99M
Market Cap 55.86M
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Verastem To Present At The Oppenheimer 27th Annual Healthcare Conference

Verastem To Present At The Oppenheimer 27th Annual Healthcare Conference

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the Oppenheimer 27 th Annual Healthcare Conference on Tuesday, March 21 st at 2:10...

Verastem To Present At The 29th Annual ROTH Conference

Verastem To Present At The 29th Annual ROTH Conference

Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the 29 th Annual ROTH Conference on Monday, March 13 th at 4:00 p.

Verastem To Present At 19th Annual BIO CEO & Investor Conference

Verastem To Present At 19th Annual BIO CEO & Investor Conference

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the 19 th Annual BIO CEO & Investor Conference on Tuesday, February 14 th at...

Groundhog Day Arrives Early

Has anybody seen Bill Murray hanging around the S&P?

Verastem Announces Dosing Of First Patient In Combination Trial Of Defactinib And Avelumab In Patients With Ovarian Cancer

Verastem Announces Dosing Of First Patient In Combination Trial Of Defactinib And Avelumab In Patients With Ovarian Cancer

Verastem, Inc., (NASDAQ:VSTM) today announced dosing of the first patient in a new clinical trial evaluating avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem's...

Verastem Announces Executive Leadership Appointments And Changes

Verastem Announces Executive Leadership Appointments And Changes

Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today announced that Hagop Youssoufian, MSc, MD, has been appointed Head of Hematology and Oncology Development.

Verastem Presents Phase 2 DYNAMO® Clinical Data At ASH 2016 Annual Meeting

Verastem Presents Phase 2 DYNAMO® Clinical Data At ASH 2016 Annual Meeting

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the presentation of results from the DYNAMO® study, a Phase 2 clinical trial evaluating the safety and efficacy...

Verastem Reports Third Quarter 2016 Financial Results

Verastem Reports Third Quarter 2016 Financial Results

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the third quarter ended September 30, 2016, and also provided an overview of certain corporate...

Verastem Announces Presentations At ASH Annual Meeting

Verastem Announces Presentations At ASH Annual Meeting

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that new data for duvelisib, an investigational, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and...

Verastem Licenses Duvelisib From Infinity Pharmaceuticals

Verastem Licenses Duvelisib From Infinity Pharmaceuticals

Verastem, Inc. (NASDAQ:VSTM) and Infinity Pharmaceuticals, Inc.

Verastem Licenses Duvelisib From Infinity Pharmaceuticals

Verastem Licenses Duvelisib From Infinity Pharmaceuticals

Transaction Adds Complementary Late-Stage Product Candidate from a Clinically Validated Drug Class to Verastem's Pipeline

Cancer Research UK, MSD And Verastem Collaborate To Trial New Combination Of Immunotherapy Drugs

Cancer Research UK, MSD And Verastem Collaborate To Trial New Combination Of Immunotherapy Drugs

CANCER RESEARCH UK has today (Friday) announced its first cross-company deal as part of its Experimental Cancer Medicine Centre (ECMC) Combinations Alliance.

Verastem To Present At Rodman & Renshaw 18th Annual Global Investment Conference

Verastem To Present At Rodman & Renshaw 18th Annual Global Investment Conference

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the Rodman & Renshaw 18th Annual Global Investment Conference on Tuesday,...

Verastem Reports Second Quarter 2016 Financial Results

Verastem Reports Second Quarter 2016 Financial Results

Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the second quarter ended June 30, 2016, and also provided an overview of certain corporate...

Verastem To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference

Verastem To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at Cantor Fitzgerald's 2nd Annual Healthcare Conference on Wednesday, July 13th at...

Study Published In Nature Medicine Highlights Potential Role Of FAK Inhibition In Pancreatic Cancer

Study Published In Nature Medicine Highlights Potential Role Of FAK Inhibition In Pancreatic Cancer

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the publication of preclinical research in the journal Nature Medicine by the Company's researchers and scientific...

Verastem Announces Changes To Its Board Of Directors

Verastem Announces Changes To Its Board Of Directors

Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today announced several changes to the Company's Board of Directors.

Verastem To Present At Upcoming Investor Conferences

Verastem To Present At Upcoming Investor Conferences

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the following upcoming investor conferences: The Jefferies 2016...

Verastem Reports First Quarter 2016 Financial Results

Verastem Reports First Quarter 2016 Financial Results

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the first quarter ended March 31, 2016, and also provided an overview of certain corporate...

Verastem Announces The Presentation Of Clinical Data At IMig 2016

Verastem Announces The Presentation Of Clinical Data At IMig 2016

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the presentation of clinical data by Professor Raphael Bueno, M.

8 Breakout Stocks Under $10 to Trade for Big Profits

8 Breakout Stocks Under $10 to Trade for Big Profits

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Verastem Names Gregory I. Berk, MD As Chief Medical Officer

Verastem Names Gregory I. Berk, MD As Chief Medical Officer

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the appointment of Gregory I.

Verastem Co-Founder, Dr. Robert Weinberg, Recognized With Two Prestigious Cancer Research Awards

Verastem Co-Founder, Dr. Robert Weinberg, Recognized With Two Prestigious Cancer Research Awards

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that Robert Weinberg, Ph.

Verastem Announces Presentation Of Scientific Data Supporting FAK Inhibition In Combination With Immunotherapy At The Keystone Symposium On Cancer Pathophysiology

Verastem Announces Presentation Of Scientific Data Supporting FAK Inhibition In Combination With Immunotherapy At The Keystone Symposium On Cancer Pathophysiology

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the oral presentation of preclinical data by the Company's scientific collaborator David G.

Verastem Announces Oral Presentation Of Data Supporting The Preferential Targeting Of Ovarian Cancer Stem Cells At The Society Of Gynecologic Oncology's 2016 Annual Meeting On Women's Cancer

Verastem Announces Oral Presentation Of Data Supporting The Preferential Targeting Of Ovarian Cancer Stem Cells At The Society Of Gynecologic Oncology's 2016 Annual Meeting On Women's Cancer

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the presentation of scientific data at the Society of Gynecologic Oncology's 2016 Annual Meeting on Women's Cancer...

Verastem To Present Data Supporting FAK/PYK2 Inhibition At The 2016 American Academy Of Cancer Research Annual Meeting

Verastem To Present Data Supporting FAK/PYK2 Inhibition At The 2016 American Academy Of Cancer Research Annual Meeting

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the presentation of scientific data at the 2016 American Association of Cancer Research (AACR) Annual Meeting being...

Verastem To Present Scientific Data Supporting FAK And PI3K/mTOR Inhibition To Target Cancer Stem Cells At The Keystone Symposium On Stem Cells And Cancer

Verastem To Present Scientific Data Supporting FAK And PI3K/mTOR Inhibition To Target Cancer Stem Cells At The Keystone Symposium On Stem Cells And Cancer

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the presentation of preclinical data and participation in an expert panel at the Keystone Symposium on Stem Cells...

Verastem To Present At 28th Annual ROTH Conference

Verastem To Present At 28th Annual ROTH Conference

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the Company will present at the 28 th Annual ROTH Conference on Tuesday, March 15 at 12:00 p.